MPC-3100 Clinical Trials

Therapeutic Area: Cancer

Phase 1 Clinical Trial

Status: Ongoing, Recruiting Patients

MPC-3100 is a potent small-molecule orally bioavailable Hsp90 inhibitor. This study was recently initiated and is designed to investigate the safety, tolerability and pharmacokinetics of MPC-3100. Patients will also be evaluated for a therapeutic response.

Visit clinicaltrials.gov for more information: http://www.clinicaltrials.gov/ct2/show/NCT00920205